Trial
NCT02393209
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
Docetaxel
Why stopped
Lack of efficacy in combination.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-07